Drugs used to treat two rare cancers have been turned down for routine use by the NHS in Scotland.
The Scottish Medicines Consortium (SMC) advised against the medicines as it ruled the cost outweighed the benefits, despite being allowed more flexibility around the decision since they are used to treat very rare and end-of-life conditions.
One of the drugs, nivolumab, also known as Opdivo, was not recommended as a routine treatment for advanced bladder cancer but was approved by the SMC last July for use on the NHS in Scotland to treat Hodgkin lymphoma, a cancer of the white blood cells.
The consortium rejected the use of obinutuzumab, also known as Gazyvaro, as another treatment option for patients with previously untreated blood cancer follicular lymphoma.
Two further drugs – arbetocin, also known as Pabal, used to reduce the risk of bleeding in mothers following a Caesarean section, and eluxadoline, also known as Truberzi, a treatment for irritable bowel syndrome with diarrhoea – were also not recommended for routine use by NHS Scotland, also on cost to benefit grounds.
SMC chairman Alan MacDonald said: “I am disappointed we were unable to accept these medicines. As the evidence of benefits in relation to cost for these medicines was lacking, they were not considered to be a good use of NHS resources.
“We know these decisions will be hard for patient groups and clinicians.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here